Mosapride overcomes the adverse reaction of cisapride to the heart, and does not prolong the Q-T interval of ECG and ventricular arrhythmia. Mosapride is a selective 5-HT4 receptor agonist, which can promote the release of acetylcholine, stimulate the gastrointestinal tract and play a role in promoting gastrointestinal motility, and improve the gastrointestinal symptoms of patients with functional dyspepsia without affecting gastric acid secretion. Proton pump inhibitor (PPI) is the most effective drug for inhibiting gastric acid secretion and preventing and treating peptic ulcer. Domestic approved proton pump inhibitors include omeprazole, pantoprazole, lansoprazole, rabeprazole and esomeprazole.